Concerted effort by governments, regulators, and industry is rapidly expanding development of new therapies for the more than 7,000 known rare diseases.
The outlook remains bright due to a favorable regulatory arena, support for biopharma-friendly legislation and development incentives, expanding scientific opportunities in key therapeutic areas such as immuno-oncology, and big pharma’s continued push to obtain innovation.
The Biotechnology Industry Organization released a report titled: Emerging Therapeutic Company Investment and Deal Trends. BIO Industry Analysis says more than 90 percent of the biopharma industry is composed of small, emerging companies. According to BIO President Jim Greenwood and E. Cartier Esham, Ph.D., executive VP of BIO’s Emerging Companies Section, it is important for the trade association to better understand early-stage investor and deal-making trends in order to determine where scientific or policy issues may be affecting the ability to maintain a robust pipeline of innovative medicines.
Here are five company stocks that some industry analysts say are under the radar and/or could be a great bargain in 2016 per BioSpace.com sources …
A listing of the top 20 pharma/biotech companies ranked by DTC spending in 2015.
Amit D. Munshi became president, CEO and interim principal financial officer of Arena Pharmaceuticals Inc. effective May 11. Munshi joined Arena’s board of directors following the company’s June 2016 annual stockholders’ meeting.
Fredrik Wiklund has been made chief operating officer of Bioniz Therapeutics Inc.
Pfizer and the Roche Group claim the #1 and #2 positions for leading the way in redefining their value to HCPs March 30, 2016 01:26 AM Eastern Daylight Time […]
The Clinical Specialist Model and the Service Rep Model are considered two of the most successful innovative approaches in S&M for pharmaceutical companies.
Newport Beach, CA — March 15, 2016 Glutenase for in-vivo gluten degradation is a leading candidate for celiac disease ImmunogenX™, a biopharmaceutical company focused on the diagnosis and treatment […]